Literature DB >> 26984178

Developments in miRNA gene signaling pathways in pancreatic cancer.

Christina Vorvis1, Marina Koutsioumpa1, Dimitrios Iliopoulos1.   

Abstract

Pancreatic cancer is a devastating malignancy that ranks as the fourth leading cause of cancer-related deaths worldwide. Dismal prognosis is mainly attributable to limited knowledge of the molecular pathogenesis of the disease. miRNAs have been found to be deregulated in pancreatic cancer, affecting several steps of initiation and aggressiveness of the disease by regulating important signaling pathways, such as the KRAS and Notch pathways. Moreover, the effect of miRNAs on regulating cell cycle events and expression of transcription factors has gained a lot of attention. Recent studies have highlighted the application of miRNAs as biomarkers and therapeutic tools. The current review focuses on latest advances with respect to the roles of miRNAs in pancreatic ductal adenocarcinoma associated signaling pathways and miRNA-based therapeutics.

Entities:  

Keywords:  antisense oligonucleotides; miRNAs; pancreatic cancer

Mesh：

Substances：

Year:  2016        PMID： 26984178      PMCID： PMC5551925          DOI： 10.2217/fon-2015-0050

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  141 in total

1.  miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting Bim expression.

Authors:  Zhen Chen; Lian-Yu Chen; Hai-Yan Dai; Peng Wang; Song Gao; Kun Wang
Journal:  J Cell Biochem       Date:  2012-10       Impact factor: 4.429

Review 2.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

3.  MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling.

Authors:  J-P Zhang; C Zeng; L Xu; J Gong; J-H Fang; S-M Zhuang
Journal:  Oncogene       Date:  2013-09-09       Impact factor: 9.867

Review 4.  Microvesicles as mediators of intercellular communication in cancer--the emerging science of cellular 'debris'.

Authors:  Tae Hoon Lee; Esterina D'Asti; Nathalie Magnus; Khalid Al-Nedawi; Brian Meehan; Janusz Rak
Journal:  Semin Immunopathol       Date:  2011-02-12       Impact factor: 9.623

5.  MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells.

Authors:  Hiroaki Nagano; Yoshito Tomimaru; Hidetoshi Eguchi; Naoki Hama; Hiroshi Wada; Koichi Kawamoto; Shogo Kobayashi; Masaki Mori; Yuichiro Doki
Journal:  Int J Oncol       Date:  2013-07-24       Impact factor: 5.650

6.  Targeting miR-21 for the therapy of pancreatic cancer.

Authors:  Flavie Sicard; Marion Gayral; Hubert Lulka; Louis Buscail; Pierre Cordelier
Journal:  Mol Ther       Date:  2013-03-12       Impact factor: 11.454

7.  Tspan8, CD44v6 and alpha6beta4 are biomarkers of migrating pancreatic cancer-initiating cells.

Authors:  Haobin Wang; Sanyukta Rana; Nathalia Giese; Markus W Büchler; Margot Zöller
Journal:  Int J Cancer       Date:  2013-02-15       Impact factor: 7.396

8.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

9.  Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.

Authors:  Jinyun Chen; Donghui Li; Ann M Killary; Subrata Sen; Christopher I Amos; Douglas B Evans; James L Abbruzzese; Marsha L Frazier
Journal:  Ann Surg Oncol       Date:  2008-11-20       Impact factor: 5.344

10.  Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.

Authors:  Anupama Mittal; Deepak Chitkara; Stephan W Behrman; Ram I Mahato
Journal:  Biomaterials       Date:  2014-05-14       Impact factor: 12.479
View more
  8 in total

1.  Propofol inhibits growth and invasion of pancreatic cancer cells through regulation of the miR-21/Slug signaling pathway.

Authors:  Zimin Liu; Jian Zhang; Guangchen Hong; Jinping Quan; Lin Zhang; Meiqin Yu
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

2.  Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis.

Authors:  Yishuo Wang; Zhongyong Liu; Qinrong Liu; Yongguang Han; Yuncai Zang; Huichao Zhang; Xuzhao Du; Tao Qin; Yuquan Wu
Journal:  Cancer Manag Res       Date:  2020-07-01       Impact factor: 3.989

3.  miR-17 as a diagnostic biomarker regulates cell proliferation in breast cancer.

Authors:  Fangliang Yang; Yuan Li; Lingyun Xu; Yulan Zhu; Haiyan Gao; Lin Zhen; Lin Fang
Journal:  Onco Targets Ther       Date:  2017-01-27       Impact factor: 4.147

4.  Quantifying the prognostic significance of microRNA-17/17-5P in cancers: a meta-analysis based on published studies.

Authors:  Fujiao Duan; Yang Yang; Weigang Liu; Jie Zhao; Xiaoqin Song; Lifeng Li; Fuqin Li
Journal:  Cancer Manag Res       Date:  2018-07-17       Impact factor: 3.989

5.  Comprehensive Assessment of the Relationship Between MicroRNA-124 and the Prognostic Significance of Cancer.

Authors:  Yadong Sun; Fujiao Duan; Weigang Liu; Zhen Peng; Liping Dai; Yajing Feng; Zhenxing Yang; Jia Shang; Kaijuan Wang
Journal:  Front Oncol       Date:  2018-07-16       Impact factor: 6.244

6.  ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.

Authors:  Anbin Wang; Haisu Dai; Yi Gong; Chengcheng Zhang; Junjie Shu; Yuandeng Luo; Yan Jiang; Wei Liu; Ping Bie
Journal:  J Exp Clin Cancer Res       Date:  2019-08-08

7.  Peptidylarginine Deiminase Inhibitor Application, Using Cl-Amidine, PAD2, PAD3 and PAD4 Isozyme-Specific Inhibitors in Pancreatic Cancer Cells, Reveals Roles for PAD2 and PAD3 in Cancer Invasion and Modulation of Extracellular Vesicle Signatures.

Authors:  Pinar Uysal-Onganer; Stefania D'Alessio; Maria Mortoglou; Igor Kraev; Sigrun Lange
Journal:  Int J Mol Sci       Date:  2021-01-30       Impact factor: 5.923

8.  miR‑539 suppresses the proliferation, migration, invasion and epithelial mesenchymal transition of pancreatic cancer cells through targeting SP1.

Authors:  Liang Xue; Yan Shen; Zhenglong Zhai; Shusen Zheng
Journal:  Int J Mol Med       Date:  2020-04-01       Impact factor: 4.101
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.